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Abstract 
Total joint replacement (TJR), such as hip and knee replacement, is a popular procedure 
worldwide. Prosthetic joint infections (PJI) after this procedure have been widely reported, 
where treatment of such infections is complex with high cost and prolonged hospital stay. In 
cemented arthroplasties, the use of antibiotic loaded bone cement (ALBC) is a standard 
practice for the prophylaxis and treatment of PJI. Recently, the development of bacterial 
resistance by pathogenic microorganisms against most commonly used antibiotics increased 
the interest in alternative approaches for antimicrobial delivery systems such as 
nanotechnology. This review summarises the efforts made to improve the antimicrobial 
properties of PMMA bone cements using nanotechnology based antibiotic and non-antibiotic 
delivery systems to overcome drawbacks of ALBC in the prophylaxis and treatment of PJIs 
after hip and knee replacement.  
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1  Introduction 
Total joint replacement (TJR), such as hip and knee replacements, are increasing worldwide 
because of growing aging population and risk factors such obesity. For example, more than 
1 million hip and knee replacement are performed annually in the United States, while more 
than 160000 replacements were performed in the UK in 2014 only. Prosthetic joint infections 
(PJI) is a serious problem that is not only reduces success rate and need for revision 
surgery, but also leads to patient death. The treatment of such infections is complex with 
aggressive surgical intervention and long antimicrobial therapy, which places huge burden 
on health care systems worldwide.  
The use of PMMA bone cement is considered the gold standard in hip and knee 
replacement, because of its mechanical performance and well-documented clinical history. 
PMMA bone cements major function is to fix the implant in adjacent bone, but also they are 
frequently used to release antibiotics for the prophylaxis and treatment of PJI. The use of 
antibiotics loaded PMMA bone cements is a standard practice in TJR with concomitant 
systemic antibiotics. Local release of antibiotics is preferred over systemic release, because 
of higher concentration of antibiotics are delivered locally avoiding side effects associated 
with systemic therapy.  
Nowadays, antimicrobial resistance to many antibiotics decreased their efficacy in the 
treatment of infections, particularly PJI. This problem necessities the development of new 
antimicrobial agents to keep up with the emergence of bacterial strains resistant to currently 
used antibiotics. Nanotechnology have been applied successfully in the improving drug 
delivery in the treatment of many diseases such as cancer [1], inflammation [2], hypertension 
[3]. Therefore, nanotechnology can serve as an approach to solve the limitations of 
antimicrobial therapy and most importantly antimicrobial resistance by developing platforms 
for efficient drug delivery, and developing new antimicrobial nanomaterials which pathogens 
may not be able to develop resistance [4]. Nowadays, the development of antimicrobial 
resistance is much faster than the discovery of new antimicrobial agents, because of 
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occurrence of resistant bacterial strains and the long process for the approval of new drugs 
which increases the demand for long-term solution. This review introduces the use of 
nanotechnology in PMMA bone cements, especially in improving the antimicrobial properties 
and providing prophylaxis from PJI after hip and knee replacements. 
 
2 Total joint replacement 
The replacement of a dysfunctional joint with an orthopaedic implant is reserved as the last 
choice for the treatment of joint diseases. Arthritic and degenerative diseases is a leading 
cause of disability worldwide [5]. The most common form of arthritis is osteoarthritis which 
affects around 15% of the population [6]. In the United States (US), more than 26 million 
people are suffering from osteoarthritis [7], while that number reaches 8.5 million in the 
United Kingdom (UK) [8]. 
Total joint replacement (TJR) is the treatment of choice for patients with end-stage arthritis 
when less invasive therapies fail to alleviate the severe pain or dysfunction of the joint 
(Figure 1) [9]. This procedure showed noticeable progress in patients’ quality of life [10,11]. 
According to the National Joint Registry [12], the predominant indication for TJR was 
osteoarthritis (more than 90% in hip and knee replacements) between the years 2003 and 
2014. Whereas, a small percentage undertook TJR for other reasons, such as avascular 
necrosis, trauma infection and inflammatory arthritis.  
The popularity of total hip and total knee replacements is increasing worldwide which places 
a huge burden on health care systems [13–15]. In the US, over 1 million hip and knee 
replacement are performed annually [16]. This number is expected to increase drastically in 
the next 20 years because of ageing as well as growing prevalence of risk factors such as 
obesity [17,18]. In the UK, the same trend is apparent; between the years 2003 and 2014 
708,644 and 772,113 primary hip and knee replacements were performed, respectively. In 
2014, 83,125 hip and 91,955 knee replacement were performed in the UK (Figure 1) [12].  
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2.1 Revision surgery 
Despite the ability of TJR to improve the quality of life and retrieve mobility to many patients, 
the life expectancy for this procedure is around 10-15 years [19–21], hence there is a need 
for revision surgeries. Revision surgeries are the joint replacements performed after primary 
TJR because of implant failure. In the US, revision surgeries account for 18% of hip and 8% 
of knee total replacements performed each year [22]. Similarly, revisions in the UK are 11 % 
(8925) of hip and 6 % (5873) of knee primary procedures performed in 2014 [12]. The main 
reasons for revision are aseptic loosening, pain, and infection. 
Compared to primary surgery, revision surgery is more complex and takes longer time to 
perform [23]. In addition, clinical and functional outcomes are poorer such as pain, joint 
stiffness and stability, muscle impairment and atrophy, with lower patient satisfaction and 
quality of life after surgery, because of complexity and nature of revision surgery [24]. Thus, 
revision is accompanied by higher complication rates, longer patient hospital stay and the 
use of a more expensive implants [25,26]. Accordingly, revision surgeries are associated 
with higher costs when compared to primary replacements, as well as relatively shorter 
survival [27]. For example, the cost of primary knee replacement is around $15000, while the 
cost of revision surgery is higher and can reach $ 24000 [26]. In the UK, health care costs 
for revision surgery were estimated to be 80 million in the year 2010 [28]. 
Infection after joint replacements is a severe problem that not only decreases the success 
rates of surgery, but also can be life threatening to patients. Despite antibiotic prophylaxis 
and operation under laminar flow, infection rates in the first two years of primary replacement 
are 1% in knee replacements, 2% in hip replacements and can reach 9% in other types of 
TJRs. Also, infection rates are significantly higher after revision surgeries (up to 40%) 
[29,30]. These percentages translate into large numbers when we look at the total numbers 
of TJRs done annually. For example, 2,400 revision procedures were performed in the UK in 
2014 due to infection [12] and 22,000 revisions of infected knee and hip replacements were 
done in the US in 2009 [31]. Prosthetic infections extend hospitalization time, readmissions 
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and length of antimicrobial treatment, hence increasing the economic burden on health care 
systems; the cost of treatment for an incident of prosthetic infection can reach $50000 which 
is more than 3 times the cost of primary surgery and 2 times the cost of revision surgery [32].  
2.2 Cemented joint replacements 
Nowadays, there are two main types for TJRs, namely, cemented and cementless joint 
replacements (Figure 2). In cemented TJRs, bone cement is widely used for fixation of 
prosthesis. Poly(methyl methacrylate) (PMMA) based bone cement is the gold standard 
material used in such procedures.  This type of TJR involves complete removal of the 
impaired joint, after that a cavity is made inside the bone. The surgeon fills the cavity with 
PMMA bone cement. Then, the metallic implant is placed and positioned in the cavity while 
the cement sets. Cementless TJRs follow the same procedure except that the implant is 
inserted in direct contact with bone without using a cement [33]. 
Bone cements are routinely used in TJRs to fasten the orthopaedic implant in place; transfer 
mechanical stresses and loads between the stiff metallic implant and bone tissue; and, 
commonly, to provide prophylaxis from post-surgical prosthetic infections by releasing one or 
more antibiotic such gentamicin or tobramycin (Figure 3) [34]. In addition, advantages for 
using bone cement include that the bone cavity does not have to be perfect match with the 
implant and the use of bone cement reduces the need for blood transfusions, because of 
reduced blood loss and the cement tamponade effect [35,36]. Furthermore, the most 
important reason for using PMMA bone cement in TJR is the outstanding long term 
survivorship (98% at ten years and 91% at 20 years) [37,38]. However, there are always 
concerns about cemented replacements because of their degradation products and debris, 
as well as deterioration of bone cement interface and third body wear [39]. These concerns 
led researchers to seek new alternatives for fixation, i.e. cementless fixation. 
Cementless replacements depend on biological fixation or osteo-integration of the implant to 
the bone; advocates of this type of fixation believe that bone ingrowth through the 
micropores of the metallic implant can achieve more durable fixation with bone (Figure 2b). 
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The claimed advantages of cementless fixation are: shorter operation time, ease of revision, 
and improved longevity for active younger patients [40]. However, cementless fixation has 
inconsistent long term results and is not regularly used in most centres, because it is 
accompanied with a high rate of revision [12,41,42]. 
2.2.1 Total knee replacement 
The use of cemented implant is the ‘gold standard’ in total knee replacement (TKR) in the 
last 3 decades and has high success rates of more than 95% at 15 years with long term 
durability [37]. Many articles reported outstanding long term results for cemented TKR. 
Crowder et al. (2005) analysed 32 patients with cemented implants, he reported survivorship 
rate of 100% in 15 years and 93.7% in 20 years after TKR procedure. Gill et al. (1997) [44] 
reported 96.5 % survivorship 18 years after the procedure in patients 55 years old or 
younger. Ritter et al. (2007) [45] also reported 97.6% success rate in the same age group 
when followed for 9.1 years. Vessely et al. (2006) [46] looked at 244 patients with cemented 
TKR, survivorship was 95.7% in 15 years after the procedure. Another study, including 265 
patients with posterior stabilized prosthesis, had 94.1% success rate over 16 years [47]. 
Many authors have directly compared cemented fixation with cementless fixation in TKR 
[48,49]. Rand et al. (2003) [50] carried out a survivorship analysis for 11606 patients at 10 
years. The success rate was 92% in patients with cemented prostheses, whereas only 61% 
success rate reported in patients without cement (P<0.0001). Barrack et al. (2004) [48] 
compared 82 cementless mobile bearing knees with 73 cemented knees, 8% of cementless 
knees were revised, while no revision found in cemented knees. Rorabeck (1999) [12] 
looked at 484 patients of hybrid and cemented knee fixation, reporting 9.6% revision rate in 
hybrid group (uncemented femur and cemented tibia), compared to 1.6% in the cemented 
group after 3 years [49]. Figure 4 shows the number of TKR in UK between the years 2003-
2014. 
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2.2.2 Total hip replacement 
Clinical studies performed on total hip replacement (THR) with cemented implants have 
convincing long term results. Berry et al. (2002) [51] reported a survivorship rate of 80% in 
25 years after the procedure in 1689 patients with cemented implant. Another study about 
cemented implant including 226 patients reported similar survival rate of 81% in 25 years 
[52]. However, a tendency towards cementless hip replacement has been seen in recent 
days, because of the significant improvement in survival rate for cementless stems. In 
patients using cementless BiCONTACT stem, the survival rate is 94.4% in 15 years [53]. 
Emerson et al. (2002) [54] looked at 181 patients with cemented and cementless hip implant. 
The survivorship was 84 % in cemented group, while it was 100% in cementless group. 
Cementless implants are specifically selected for young active patients who have greater 
physical loads with greater failure rates secondary to loosening, whereas cemented implants 
are used for older patients with poor bone quality [55,56]. Figure 5 shows the number of 
THR in the UK between the years 2003-2014 [12]. 
2.3 PMMA bone cements 
Poly (methyl methacrylate) polymer (PMMA) is a polymer based on methyl methacrylate 
(MMA) monomer units. PMMA cement is prepared by mixing two constituents together:  
PMMA polymer powder and liquid MMA monomer (Figure 6). After mixing the two 
components, the hardened bone cement is formed by an exothermic free radical 
polymerization reaction, as the liquid monomer polymerizes around the pre-polymerized 
powder producing heat [57]. The heat of the setting reaction can reach (66-82.5 ºC). The 
setting time for the cement is relatively short (less than 15 min) and the cement must be 
inserted into the bone before cement hardening, otherwise the procedure cannot be 
completed [58]. Premature polymerization of the liquid component may happen because of 
exposure to heat and light. Therefore, Hydroquinone is added as a stabilizer to prevent 
polymerization before mixing of the cement constituents. Benzoyl peroxide is added to the 
powder to initiate the free radical polymerization reaction, while N, N-Dimethyl para-toluidine 
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(DMPT) is added as an accelerator to facilitate the polymerization reaction between the 
polymer and monomer at room temperature (Chaudhry & Dunlop, 2012). Barium sulphate 
(BaSO4) or zirconium dioxide (ZrO2) are added as radiopaque agent to allow X-ray imaging 
because PMMA is not radiopaque [59].  
At present, many commercial bone cements are marketed by different manufacturers (Table 
1). The main differences between different formulations are the molecular weight of PMMA, 
the ratio between homopoylmer and copolymer, the ratio between powder and liquid, the 
radiopacifier and other additives such as antibiotics.  Different copolymers of different acrylic 
monomers are added to modify the mechanical properties of the cement, such as MMA, 
styrene and Ethyl methacrylate [60]. Table 1 shows the composition of some commercially 
available PMMA bone cements. 
The main drawback of PMMA bone cement is the absence of bone bonding ability, i.e. 
bioactivity. This can lead to the formation of fibrous tissue around the implant and a space 
for the wear particles to accumulate [61]. As a result, bone resorption around the implant 
causes loosening and failure of the implant after a long period of time, which is the most 
commonly reported reason for revision in cemented replacements [12]. Despite the 
extensive research done on developing alternatives for PMMA in THR and TKR, PMMA 
stays to be the biomaterial of choice in TJRs since the 1960s, because of its acceptable long 
term survivorship and long-established clinical history as well as excellent mechanical 
properties [57]. Extensive research has been directed on developing new bioactive bone 
cements that integrate with bone, and improving the biocompatibility as well as mechanical 
properties of PMMA bone cements [62,63].  
One of the examples on bone cements with bioactive properties is calcium phosphate bone 
cement (CPC), which has been studied since 1980s [64]. Their poor mechanical properties 
such as strength, toughness and brittleness limited their application to low load-bearing 
arthroplasties e.g. craniofacial and maxillofacial surgeries (Table 2). Despite CPCs bioactive 
properties, their inferior mechanical properties are not sufficient to replace the use of PMMA 
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in high load-bearing arthroplasties such as knee and hip replacements [65,66]. The 
mechanism for setting reaction involves a dissolution-precipitation process that occurs at 
body temperature, without causing tissue necrosis in the surrounding tissue unlike the 
exothermic setting reaction for PMMA [67]. Despite the presence of many CPC formulations, 
the final product only could be either brushite or hydroxyapatite. Brushite is a metastable 
form that may transform into hydroxyapatite at pH>4 in vivo [68]. CPCs are microporous in 
nature which helps in the penetration of biological fluids, hence they are resorbable and can 
be replaced by bone [69]. In addition, the micropores enhance the ability of CPCs to load 
drugs which is an appealing option for any type of biomaterial [70,71].  
Apatite/wollastonite is another bioactive bone cement that has been researched for use in 
knee and hip replacements. Apatite/wollastonite glass bioactive ceramics have currently 
many medical applications and used as bone filler or bulk material [72]. Also, they have 
higher mechanical properties than other bioactive ceramics and cortical bone (Table 2). 
However, they cannot be used in high load arthroplasties such as hip and knee 
replacements, because their fracture toughness is lesser and elastic modulus is greater than 
those of cortical bone [73].  
Dental cements have been also researched for orthopaedic application such as glass 
polyalkenoate and Bioglass [74,75]. Glass polyalkenoate is a dental cement with good 
mechanical properties (Table 2), but the release of aluminium from the glass phase causes 
defective bone mineralization and limits their use in the orthopaedic field [76]. In order to 
avoid this problem aluminium was replaced with Zn, as it has a positive effect on osteoblast 
proliferation and increases bone mass. However, Zn based glass polyalkenoate has 
substantially inferior mechanical and setting properties compared with aluminium containing 
counterparts [75]. Moreover, resin modified glass polyalkenoate, another biomaterial, was 
developed to improve the poor mechanical properties of conventional glass polyalkenoate. 
Although it has good mechanical properties, they suffer from volumetric shrinkage after 
curing which causes mechanical failure at the implant interface [77,78].  
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None of the previously mentioned bioactive cements have the required mechanical 
properties to be used in high load bearing arthroplasties. Despite the lack of bone-bonding 
properties of PMMA, it is still the only biomaterial to be used in cemented hip and knee 
arthroplasties. Therefore, PMMA fails to achieve a long-lasting replacement making aseptic 
loosening the most common cause for revision. Newly developed bone cement should have 
both bone-bonding properties (bioactivity), as well as mechanical properties that match 
those of bone and optimally have antimicrobial properties [79]. 
2.4 Prosthetic infections 
The success of TJRs in relieving pain and improving the quality of life for patients is 
increasingly growing. Infection is considered the most serious problem after joint prosthesis 
implantation, which decreases success rate of the surgery and can be life threatening to 
patients in some cases [29]. Prosthetic infections are difficult to diagnose and occur at 
variable times after the primary surgery. Management of prosthetic infections is complex and 
needs multiple procedures and prolonged antimicrobial therapy with poor functional outcome 
[30]. This places considerable burden on medical resources and health care expenditure, 
because of the high cost of prosthetic joint infection incidence treatment that can reach up to 
$50000 [32]. Efforts have been made to reduce the risk of prosthetic infections such as the 
use of perioperative antimicrobial prophylaxis and surgical laminar airflow environment, 
however the incidence of prosthetic infection is still high and can reach up to 2% in total hip 
and knee replacement, and even higher after revision surgeries (up to 40%) [29]. 
Prosthetic infections have 3 classifications based on the onset of infection, namely, (i) early, 
(ii) delayed, (iii) late infections. For early infections, the signs and symptoms of infections 
appear in the first 3 months after surgery, and the infection are usually because of bacterial 
contamination during or after surgery caused by highly virulent microorganisms. Early 
infections account for up to 45% of prosthetic infections. In delayed infections, the first signs 
and symptoms appear after 3 months to 2 years after surgery. The causes of delayed 
infections are low virulent microorganisms inoculated during surgery. In late infections, the 
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onset starts after 2 years from surgery, and caused by seeding via the blood from an 
infection in other body parts such as skin, respiratory or urinary tract infections [80–82]. 
Biofilm formation is the typical mode of growth for bacteria involved in prosthetic infections, 
which adds to the difficulty and length of treatment. The microorganisms in biofilms form 
ordered and complex clusters enclosed by a hydrophilic polymeric matrix [30,80]. Biofilms 
shelter microorganisms form antibiotics and host immune defence, as well as increase 
bacterial resistance and reduce susceptibility to antibiotics by 500-5000 times compared to 
planktonic, free floating bacteria [29]. In addition, the implant acts as a binding site for 
bacterial accumulation into biofilms and decreases the minimum dose of bacteria needed to 
cause infection [30]. 
The most commonly encountered bacteria in prosthetic joint infections are coagulase-
negative staphylococci (30-43%) and Staphylococcus aureus (12-23%), followed by 
streptococci (9-10%), Gram-negative bacilli (3-6%), enterococci (3-7%), and anaerobes (2-
4%). Polymicrobial infections, which usually occur postoperatively, are seen in (10-12%) and 
they are difficult to treat.[80,83]. 
2.4.1 Treatment 
The treatment of prosthetic infection aims to relieve patients from pain, restore joint mobility 
and eradicate infections. Treatment of such infections is typically challenging and complex 
with combined aggressive surgical interventions and antimicrobial therapy, which make it 
hard to achieve all of the 3 aims together. Management of prosthetic infections should be 
customised for each patient and usually includes one of 3 main types of surgical 
interventions [29,84]. First, prosthetic retention with debridement of all infected tissue and 
irrigation, which is a choice for early postoperative or late haematogenous infections with 
retention of the prosthesis and long term antibiotic treatment  [85,86]. Second, prosthetic 
exchange, the most frequently used, by one stage or two stage revision. In one stage 
revision, the removal of all foreign material debridement and reimplantation of a new 
prosthesis are done in the same procedure [87]. While in two stages revision, the removal of 
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foreign material and debridement are done, and the reimplantation of a new prosthesis is 
delayed for a variable period of time (typically after > 6 weeks) [88]. Third, salvage 
procedure including resection arthroplasty, arthrodesis and amputation which are the last 
choice when infection management is not achievable by the previously mentioned 
interventions [89]. 
 Two stage revision has become the standard procedure in the treatment of deep tissue 
prosthetic infections [90]. The two-stage approach gives sufficient time for debridement and 
removal of the infected tissues, the determination of the infecting microorganism and its 
sensitivity to antibiotics, modifying the antimicrobial therapy before reimplantation. However, 
extended hospitalization increases the surgery costs, while delayed mobilization and risk of 
other surgery is cautiously considered, particularly in elderly people [91].   
 In two stage surgery, the use of antibiotic-impregnated spacers is considered the gold 
standard for the eradication of infection and avoiding limb shortening [92,93]. Spacers are 
bone cement pieces that is placed in the joint place to prevent muscle contractions and 
preserve their length. The use of a temporary spacer in two-stage surgery in knee 
replacement gives the patient the ability to move, also provides good alignment of the knee 
between the two stages [94,95]. Success rates with the use of antibiotic impregnated PMMA 
interim spacer/prosthesis are reported to be higher than 90% [96]. The advantage offered by 
such spacer is delivering high level of antibiotic locally, while maintaining joint mobility [97]. 
Table 3 shows common antibiotic combinations used for the impregnation of PMMA bone 
cement spacers. 
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2.4.2 Prophylaxis 
Antibiotic loaded bone cements (ALBC)s are routinely used in hip and knee TJRs not only in 
the treatment of prosthetic infections, but also to prevent infections after cemented 
replacements, and their use become a well-established practise along with peri-operative 
systemic antibiotics [98,99]. More than 90% of surgeons use ALBC in primary TKR in the UK 
[100], Sweden [101], and Norway [99]. The use of ALBC in knee replacements reduces the 
percentage of prosthetic infection compared to bone cements lacking antibiotics [102,103]. 
Similarly, the use of ALBC in hip replacements improves survivorship by reducing the risk of 
prosthetic infections after primary replacements [104,105]. A meta-analysis evaluating the 
efficacy of ALBC in hip replacements reported that the use of ALBC reduces prosthetic 
infections after primary hip replacements from 2.3% to 1.2%, and 40% after revision [98]. 
Local antibiotic release from the bone cement gives higher concentration in the joint 
compared with systemic antibiotics, which are hindered by limited blood circulation at the site 
of implantation [106,107]. Moreover, local delivery of antibiotics avoids the adverse effects of 
high antibiotic levels in the blood, such as nephrotoxicity and ototoxicity [108]. Hence, ALBC 
provide an alternative strategy for the prosthetic infection prophylaxis. 
The antibiotic loaded acrylic bone cements available commercially can be either a premixed 
powder, where the antibiotic is blended with the cement powder by the manufacturer, or an 
off-label formulation. In off-label formulations the antibiotic powder is provided separately to 
be mixed with the cement by the surgeon during surgery [109,110]. Low concentrations of 
the antibiotic (0.5-1.0 g per 40 of powder) are used for primary arthroplasty prophylaxis and 
second stage of a two-stage revision arthroplasty, while high concentrations (2.0-4.0 g per 
40 g powder) are used for the treatment of existing active infection [111]. 
The choice of antibiotic for incorporation in the bone cement depends on several factors. 
Desirable antibiotic characteristics include availability in powder form, wide antibacterial 
spectrum, thermal stability to withstand the high exothermic temperature of the setting 
reaction, elution from the bone cement for a prolonged period, low allergic effects and most 
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importantly low influence on the mechanical properties of the bone cement [112]. Among the 
antibiotics used, which usually meet these criteria, are aminoglycoside (gentamicin and 
tobramycin) [113] and glycopeptides (vancomycin) [114]. The combination of antibiotics from 
more than one group gives a wide antimicrobial spectrum [115]. Table 4 shows some of the 
commercially available bone cement brands and the incorporated antibiotics. 
 
2.5 Limitations for antibiotic loaded bone cements 
2.5.1 Antibiotic elution properties from bone cement 
The elution kinetics of antibiotics from PMMA bone cements are highly variable and depend 
on many factors. Different brands of bone cements come with different compositions, 
viscosities and porosities [116,117]. Hence this leads to differences in their ability to release 
antibiotics. Porosity is introduced into the cement by the formation of air bubbles during the 
exothermic setting reaction and depends on the viscosity and manipulation technique [118]. 
Porosity increases antibiotic elution from bone cement but at the same time has a negative 
impact on it’s mechanical properties [119]. Among other factors affecting elution kinetics is a 
type of antibiotic used or antibiotic combinations [115,120]. 
The ideal ALBC should sustain the release of antibiotic at high concentrations for a long time 
to prevent early onset infections and avoid the development of resistant bacterial strains 
[112]. However, the antibiotic release from ALBC, in reality, is characterised by initial 
uncontrolled burst release for the first few hours after surgery. Subsequently, the antibiotic 
release drops rapidly below inhibitory levels within few days, and does not provide long term 
sustained delivery of antibiotics [121–124]. Moreover, more than 90% of the loaded antibiotic 
may still be entrapped within the hydrophobic PMMA matrix [125,126]. The initial burst 
release occurs when the ALBC is exposed to fluid surrounding the joint and governs mainly 
by a surface phenomenon because of the presence of antibiotic agglomerates on the 
17 
 
surface of bone cement, while the sustained release over the next few days is a bulk 
phenomenon and more affected by the porosity of cement [127]. 
2.5.2 Development of antimicrobial resistance 
Antibiotic burst release from the bone cement is followed by slow release of antibiotic at low 
concentrations below the minimum inhibitory concentration needed to kill bacteria [122,124]. 
This slow release increases the chances for selecting resistant microbial strains which raises 
concerns about future effectiveness of antibiotics used in ALBCs [128,129].  The bacterial 
strains selected at low antibiotic concentrations are generally highly resistant [130]. Some 
experimental studies show the capacity of pathogens to grow on the surface of ABLC and 
the ability to form biofilms [30,127]. Anguita-Alonso et al. (2005) investigated the 
susceptibility of Staphylococci taken from patients with prosthetic infection against 
gentamicin and tobramycin (aminoglycoside antibiotics) [131]. 41% and 66% of bacteria 
were resistant to gentamicin and tobramycin respectively. Corona et al. (2014) compared 
antibiotic susceptibility between patients having infection for the first time and patients with 
previous use of ALBC and found a significantly higher resistance, indicating the risk of 
selecting aminoglycosides resistant strains after using ALBC [132]. 
2.5.3 Antibiotics effect on the mechanical properties of bone cement 
Addition of antibiotics to bone cements has a negative impact on their mechanical 
properties. Small quantities of antibiotics (< 1g per 40 g of bone cement) slightly decrease 
compressive and bending strength of bone cement but stays in the acceptable range stated 
by the standard ISO 5833:2002, while high antibiotic quantities cause a significant decrease 
in the mechanical properties [110,133]. The acceptable ranges for the mechanical properties 
of a set bone cement are > 70 MPa compressive strength, > 1800 MPa bending modulus 
and >50 MPa bending strength [134]. High dose ALBCs (>2g per 40g cement) are only used 
temporarily in spacers for the treatment of prosthetic infection in two stage surgery, because 
their poor mechanical properties, while low dose ALBCs (< 2g per 40g cement) are used for 
prophylaxis where mechanical properties are important for implant fixation [121,135].  
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Persson et al. (2006) reported a detrimental decrease in the bending (-22%) and fatigue 
strength (-15%) of bone cement when vancomycin was added at 2.5% w/w [136]. He et al. 
observed that the use of gentamicin at concentrations below 3% had no significant effect on 
the compressive and elastic modulus of bone cement; however, higher concentrations 
caused significant decrease in these two parameters [137].  
3 Novel bone cement formulations 
3.1 Role of nanotechnology 
Currently used antibiotics have many limitations including microbial resistance, narrow 
therapeutic index, cytotoxicity and side effects linked to non-selectivity in their mode of 
action and poor release profiles from carrier systems. Nanotechnology, which refers to the 
production and application of materials in the size range (1-100nm), has been used in the 
treatment of many diseases such as cancer [1], inflammation [2], hypertension [3]. The 
success of nanotechnology in improving drug release in the treatment of many diseases 
makes it an appealing approach for application in antimicrobial therapy. Nowadays, the 
development of antimicrobial resistance is rapidly increasing compared to the discovery of 
new antimicrobial agents. Therefore, the development of nanotechnology drug delivery 
systems or new antimicrobial nanomaterials can be used to overcome the problems of 
inefficient delivery of antimicrobial agents and resistance to currently used antimicrobials [4].  
 Novel nanotechnology drug delivery systems offer many advantages to overcome the 
current challenges with antimicrobial therapy. Nanoparticles have unique physicochemical 
properties such as large ratio of surface area to mass, small size, and ease of structural or 
functional modification. The antibiotics can be loaded into nanoparticles by physical 
encapsulation, adsorption or chemical conjugation where the drug release profiles can be 
significantly altered compared to free drug counterpart, enhancing poor delivery of drugs and 
sustaining release [138]. In addition, specific microbial resistance mechanisms to antibiotics 
can be overcome using nano-systems, which act on multiple biological pathways present in 
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most types of bacteria [139]. Moreover, nano-carriers can be used for the delivery of multiple 
antibiotics to provide synergistic effect against resistant strains [140]. Nanoparticles labelled 
antibiotics increase binding to bacteria and the concentration at the site of infection. These 
improvements can be attributed to the enhanced solubility of drugs and controlled release 
profiles. Also, nano-systems decreases side effects by enhancing cellular internalization and 
uniform distribution in the target tissue, and improving the pharmacokinetic profiles and 
patient compliance to antibiotics [141]. Compared to antibiotic synthesis, the preparation of 
nanoparticles is cost-effective giving stable formulations for long term storage. Although, 
antibiotics can be degraded easily at harsh conditions, nanoparticles can withstand harsh 
conditions such as high temperature and sterilization [4]. 
3.2 Nanotechnology based antibiotic based antimicrobial bone cements 
Nanotechnology based antibiotic delivery systems is a becoming a new approach for solving 
the limitation of antimicrobial therapy. Nanoparticles can be used to improve the release 
kinetics of antibiotics by enhancing delivery and providing controlled release. These 
improvements are attributed to large area to mass ration and small size, and different ways 
available for modification and for antibiotic loading [138]. Many nanotechnology-based 
antibiotic carriers have been researched to improve the antibiotic release profile from PMMA 
bone cement including liposomes [142], mesoporous silica [143], carbon nano-tubes, 
hydroxyapatite nano-rods and clay nanotubes [144].  
Although liposomes have miscibility problems in non-aqueous environment because of their 
hydrophilic surface, they were used to improve gentamicin distribution within PMMA bone 
cement. Liposomes have been largely used as drug carrier in aqueous suspensions, and 
have miscibility problems when mixed with PMMA leading to phase separation [145]. Ayre et 
al. (2015) [142] solved the problem of phase separation using Pluronics on the surface of 
liposomes (Figure 7)
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Pluronics are surfactants made of interconnected chains of polyethylene oxide (PEO) and 
poly propylene oxide (PPO) subunits. It is hypothesized that the hydrophilic PEO will attach 
to the hydrophilic surface of liposomes, while the PPO will attach to the hydrophobic matrix 
of PMMA. Liposomes were suspended to the liquid MMA part of before mixing with PMMA 
powder. Moreover, pelleted liposomes of 100 nm size were prepared by extrusion and ultra-
centrifuged with 3 different Pluronic surfactants (L31, L43, and L61). Gentamicin release 
from liposomal bone cement was sustained for 30 days with 22% of the loaded antibiotic 
released compared to 9% from commercial formulation. Gentamicin release was 
characterized by bust release in the first 72 hrs for commercial bone cement, while liposomal 
cement showed nearly linear release profile. Despite the slight reduction in compressive 
strength, the liposomal formulation enhanced the toughness, bending strength and Vickers 
hardness of cement when compared to Palacos R+G. The addition of liposomes improved 
the dispersion of gentamicin in bone cement and improved the mechanical properties as 
well.  
In another work, Shen et al. (2016) [143] mesoporous silica nanoparticles (MSN) were used 
to improve the release kinetics of gentamicin from PMMA bone cement. The presence of 
10% MSN enhanced the release for more than 60% of loaded gentamicin over 80 days. 
Furthermore, the concentration of MSN was found to be crucial to build a nano network to 
facilitate the diffusion of gentamicin molecules as supported by images (Figure 8). Hence, 
MSN concentration below 6 % could not improve gentamicin release. The compressive 
strengths of MSN functionalized bone cements is nearly the same as the commercial bone 
cement. However, the bending modulus is reduced by 10%. Moreover, the 10% MSN bone 
cement was cytocompatible with 3T3 mouse fibroblasts, showing 96% cell viability in 3T3 
mouse.  
Carbon nanotubes (CNT) were also tested for enhancing gentamicin release from PMMA 
bone cement. Although 5% (CNT) loaded bone cement lead to 75% release of gentamicin 
for 60 days, the compressive strength is reduced by 90% compared with the commercial 
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bone cement. Furthermore, CNT showed high toxicity to 3T3 mouse fibroblasts with 85% cell 
viability. Cytotoxicity of CNT is among the most concerns for its application in biological 
systems and it has also attracted more attention in recent investigation [147]. In the same 
work, hydroxyapatite nano-rods (HAP) were loaded with gentamicin by wet impregnation and 
loaded into PMMA bone cement at 32% concentration. At this concentration, 75% 
gentamicin was released over 60 days. Despite low cytotoxicity of HAP, as it is one of major 
compositions of bone structure, the compressive strength is decreased by 50% compared to 
the commercial bone cement.  
In another study, clay nanotubes Halloysite is used to improve gentamicin release from 
PMMA bone cement [144]. Halloysite is a naturally occurring nanotube with a length of 500–
1000 nm, diameter of 50 nm, and lumen of 15 nm. Therefore, it is highly biocompatible as 
confirmed by blue cell essays on HeLa and MCF-7 cell lines [148]. PMMA bone cement was 
loaded with 5-8% Halloysite and with 10-15% gentamicin. The release profile was 
characterised by burst in the first few days. After that, gentamicin release slowly continued 
for 250 hours. Furthermore, the addition of 5-7% Halloysite nanotubes improves the tensile 
strength and adhesive properties, except for flexural strength which is slightly reduced with 
higher concentration such as is 5% which gives both higher tensile strength and good 
flexural properties. Table 5 summarizes the mechanical properties of previously mentioned 
nanocomposites and Table 6 is a list of different nanotechnology based antibiotic loaded 
PMMA bone cements. 
3.3 Non-antibiotic based antimicrobial bone cements 
Quaternary ammonium compounds attracted research because of their antimicrobial 
properties and stable structure [149]. Chitosan quaternary ammonium nanoparticles 
impregnated bone cement showed antimicrobial activity against viable bacterial at a 
concentration of 15% w/w [150]. In another study, hydroxypropyl trimethyl ammonium 
chloride chitosan loaded (HACC) bone cement inhibited biofilms caused by methicillin-
resistant Staphylococcus strains showing in vitro release for 120 hours [151], with enhanced 
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physical and osteogenic properties [152]. HACC-loaded bone cement was further evaluated 
in vivo for the treatment of Methicillin-resistant Staphylococcus epidermidis infection of the 
tibial metaphysis in a rabbit model, and exhibited effectiveness in the inhibition of bone 
infections [153]. One quaternary ammonium dendrimer of tripropylene glycol diacrylate 
(TPGDA) was mixed with bone cement at a concentration of 10%. At this concentration, 
TPGDA modified bone cement showed antimicrobial activity for 30 days. In addition, the 
dendrimer bone cement composite was potent to kill 108 CFU/mL of bacteria on regular 
intervals of 5 days for a month. However, the addition of dendrimer resulted in a reduction of 
compressive strength (>15%) compared to the original sample. Furthermore, the MTT assay 
for the dendrimer modified bone cement showed 12.5% reduction in the viable cells 
compared to the control, and cytotoxicity needs to be further determined [149]. Table 7 
summarizes some examples of antimicrobial bone cements with potential application in total 
joint arthroplasties. 
Quaternary ammonium chitosan derivative nanoparticles (QCS) achieved a 103-fold 
reduction in the number of viable bacterial cells upon contact with the surface when added at 
concentration of 15% to bone cement. Chitosan in the form of nanoparticles is better in 
preserving the mechanical properties of the bone cement compared to powdered chitosan, 
i.e. Young modulus and bending modulus is >90% of the original bone cement values. When 
the CS (powder not NP) loading was decreased to 15%, the Young’s modulus and bending 
modulus are about 90% of the corresponding properties of the original bone cement. This 
can be explained by the homogenous distribution of nanoparticles inside the bone cement 
matrix, which minimizes the macroscopic cracks in cement mantle. QCS nanoparticles 
showed higher antimicrobial activity compared to chitosan nanoparticles at the same 
concentration, where the viable cell number declined by about three orders and two orders 
of magnitude, respectively. However, The MTT assay showed that there is no significant 
difference in cytotoxicity between the CS NP, QCS NP and the non-toxic control [150].   
23 
 
Silver nanoparticles have many applications in medical field as safe and effective 
antimicrobial agents, such as bandages, catheters and surgical scrubs. However, systemic 
administration of silver nanoparticles can cause various health problems when it reaches 
toxic levels in different body organs [154]. Consequently, local delivery of silver may 
decrease the adverse effects of high silver levels in the blood. Oei et al. (2012) [155] 
investigated the antimicrobial properties of a PMMA bone cement impregnated with silver 
nanoparticles. Despite in vitro release of silver ions for 28 days and broad spectrum 
antimicrobial activity, the mechanical properties of bone cement was negatively affected at 
the concentration used (1% w/w) and showed lower bending modulus. Silver nanoparticles 
prepared with different capping agents were studied for bone cement impregnation. 
Prokopovich et al. (2015) [156], reported a broad spectrum antimicrobial activity of silver 
nanoparticles capped with oleic acid at low concentrations of 0.05 w/w %, without affecting 
the mechanical properties and cytotoxicity of the bone cement. Similar preferable 
antimicrobial and mechanical properties were identified when silver nanoparticles capped 
with tiopronin were impregnated in PMMA bone cement at a concentration of 0.1 w/w % 
[157]. 
 In another study, Perni et al. (2015) [158] developed a propyl paraben nanoparticle loaded 
bone cement at a concentration of 7% w/w. Nanoparticles at this concentration exhibited 
wide spectrum antimicrobial killing with no detrimental effect on mechanical properties and 
cytocompatibility. 
4 Drug delivery systems and nano-formulations for potential use 
in bone cements 
Some approaches to prolong drug release have been conducted but efficacy has not been 
tested in bone cement yet (Table 8). One of the novel approaches for enhancing the delivery 
of aminoglycoside antibiotics is Layer by Layer assembly (LbL). LbL has numerous 
applications in drug delivery [159]. This coating technique is a versatile method and involves 
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the deposition of alternative oppositely charged polyelectrolytes on different substrates, 
allowing control of the thickness and composition of coating at nanoscale level in a 
reproducible manner [160,161]. Tamanna et al. (2015) [162] managed to control the release 
of gentamicin from gentamicin loaded mesoporous silica nanoparticles coated using LbL 
technique. The coating polyelectrolytes were polystyrene sulfonate (PSS) and poly 
(allylamine hydrochloride) (PAH). The coated layer controlled drug release for 10 days with 
no burst release compared to the same gentamicin loaded nanoparticles without coating. In 
another work, Lichter & Rubner (2016) [163] developed an antimicrobial LbL assembly 
without the addition of biocidal species, by optimizing the conditions during and after layers 
deposition in order to expose the cationic charges needed for antimicrobial activity. 
Multilayers of PAH, PSS and poly(acrylic acid) (PAA) were constructed at high pH and 
subsequently immersed in low pH solutions, which showed antimicrobial activity against S. 
epidermidis and E. coli. In a similar work, Kovačević et. al. (2016) [164] studied the changes 
in surface material properties by using LbL coating, and their effect on the bacterial adhesion 
of P. aeruginosa. Multilayers of PAH and PSS were built on the silica surface, where the 
polyelectrolyte multilayers terminating with negatively charged polyelectrolyte showed less 
bacterial adhesion on the surface.   
Mu et al. (2016) [165] evaluated the antimicrobial properties of phosphatidylcholine-
decorated Au nanoparticles loaded with gentamicin (size 180 nm), which showed broad 
spectrum activity and inhibition of biofilm formation. The presence of phosphatidylcholine on 
the surface facilitated the electrostatic binding of gentamicin. The nanoparticles were more 
efficient in the inhibition of Pseudomonas aeruginosa and Staphylococcus aureus biofilm, 
when compared to gentamicin or phosphatidylcholine Au nanoparticles without gentamicin. 
Gentamicin release continued for 7 days in buffer media pH 7.4, and the loading efficiency 
was 38µg/ml (gentamicin/Au). Cytocompatibility studies were done using RAW 264.7 cells 
and the nanoparticles were nontoxic and can be engulfed by macrophages. 
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Fan et al. (2016) [166] loaded chlorhexidine on Ca-silicate mesoporous nanoparticles (size 
78.6 nm) using mixing-coupling technique. The nanoparticles were able to release 
chlorhexidine as well as Ca2+ and silicate2- ions for up to 9 days in simulated body fluids. 
They showed antimicrobial activity against Enterococcus faecalis which is commonly 
reported to be involved in root canal infection. The nanoparticles did not show any negative 
effect on cell proliferation and showed in vivo mineralization effect, which give them the 
potential to be used in intra-canal defects or bone infections. 
Poly (lactide-co-glycide) (PLGA) is hydrophobic biodegradable and biocompatible polymer 
that is approved for clinical use. Abdelgahany et al. (2012) [167] prepared gentamicin PLGA 
nanoparticles through emulsion evaporation method, using two approaches: water/oil/water 
and solid/oil/water. The size for the nanoparticles were 251 nm and 359 nm, respectively, 
with loading efficiency reached up to 22.4 µg/ml. Gentamicin release from the nanoparticles 
continued for up to 16 days at pH 7.4. In addition, the nanoparticles showed antimicrobial 
activity against P. aeruginosa planktonic bacteria and biofilms, as well as in vivo infected 
mice model.   
Kurtjak et al. (2016) [168] loaded gallium nanoparticles (size 22nm) into hydroxyapatite 
nano-rods bioactive composite through ultrasonic emulsification. The gallium nanocomposite 
showed better antimicrobial properties against Pseudomonas aeruginosa, when compared 
to silver nanocomposite, as illustrated by microdilution assay and MIC determination. Also, 
gallium nanoparticles had lower toxicity for human lung fibroblast and mouse fibroblasts.  
 
5 Conclusion 
The currently used ALBCs have many limitations in terms of antimicrobial performance and 
elution of antibiotics from PMMA matrix. In addition, there is a need for the development of 
new antimicrobial agents and antibiotic delivery systems to overcome the emergence of 
resistant bacterial strains encountered in PJIs. The use of nanotechnology in antimicrobial 
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treatment is attracting more attention in literature. As a result, its application in ALPC is 
increasing to improve the properties of bone cement and its antimicrobial performance. The 
field of nanotechnology based antimicrobial medicine and its application in ALBC is still in its 
infancy, and not well researched as the case in nano-cancer medicine and cardiovascular 
drug targeting. However, nanotechnology shows promising results in improving antibiotic 
release and the antimicrobial properties of PMMA bone cement, while preserving its other 
characteristics needed for physiological performance. The ideal ALBC should sustain the 
release of antibiotic or antimicrobial agent at high concentration for > 30 days to prevent 
early and delayed onset postsurgical infections. At the same time, the addition of the 
antimicrobial species should not compromise the mechanical properties of bone cement, and 
it’s cytocompatibility with the surrounding tissue. The incorporation of gentamicin loaded 
MSN in the bone cement is a clear example of how a nanotechnology-based approach 
improved the release kinetics of gentamicin to reach extended release for 80 days, whilst 
preserving the mechanical properties and cytocompatibility of the bone cement [143].   
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Tables  
Table 1. Composition of some commercially available PMMA bone cements.  
Constituent* Cemex® 
XL 
Genta LV 
EnduranceTM 
Gentamicin 
Copal® Palacos® 
R+G 
SmartSet® 
GHV 
Liquid 
MMA 98.20 98.00 97.98 97.98 97.50 
N,N dimethyl-p-toluidine 
(DMPT) 
1.80 < 2.00 2.02 2.02 < 2.50 
Hydroquinone 75 75 75 75 75 
Chlorophyll - - 0.002 0.002 - 
Powder 
Poly(methyl methacrylate) 
(PMMA) 
82.78 65.28 - - - 
Methyl methacrylate 
(MMA)/styrene 
co-polymer 
- 18.65 - - - 
PMMA/MMA co-polymer - - 82.65 82.15 80.46 
Benzoyl peroxide (BPO) 3.00 1.85 0.75 0.78 0.96 
Barium sulfate 10.00 10.00 - - - 
Zirconium dioxide - - 10.03 15.01 14.37 
Gentamicin sulfate 4.22 4.22 3.76 2.06 4.22 
Clindamycin hydrochloride - - 2.82 - - 
Chlorophyll  - 0.002 0.002 - 
 
*The amount of each constituent of a cement is in wt. /wt. %, except for hydroquinone, which 
is ppm. 
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Table 2. Mechanical properties for some bioactive cements, PMMA and human bone 
(cortical and cancellous bone). 
 
 
Strength (MPa) Young’s 
modulus 
(GPa) 
Fracture 
toughness, KIC 
(MPam1/2) 
Reference 
Compressive Bending 
Bioglass® (45S5) - 42 35 - [73] 
glass polyalkenoate 175.21 - 12.82 0.63 [169] 
Hydroxyapatite 39-103 - 4.5-9 0.15-0.5 [170] 
Apatite/wollastonite 1080 220 118 2.0 [73] 
PMMA 73-117 50-125 2.552 1.03-2.32 [134,171] 
Human 
bone 
Cancellous 2-12 - 0.05-0.5 - [73] 
Cortical 100-230 50-150 7-30 2-12 [73] 
 
Table 3. Antibiotic combinations used for the impregnation of PMMA bone cement spacers 
for hip and knee prosthetic infections. 
 
 
 
 
 
 
 
 
 
 
 
Reference Antibiotic combination used per 40g PMMA  
[172] 0.76 g gentamicin + 1 g vancomycin 
 [173,174] 0.25 g gentamicin + 2 g vancomycin 
[175] 1.2-4.8 g tobramycin + 1-2 g vancomycin 
[176] 4 g vancomycin + 2 g piperacillin 
[177–179] 3.6-4.8 g tobramycin + 4 g vancomycin  
[180] 4.5 g piperacillin-tazobactam + 2 g vancomycin 
+ 1 g erythromycin  
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Table 4. Some of the commercially available antibiotic loaded bone cement brands. 
 
Brand Antibiotics Antibiotic used 
per 40g PMMA 
Manufacturer 
Palacos R+G Gentamicin 1.0 g Zimmer 
Palacos LV+G Gentamicin 1.0 g  Zimmer 
CMW 1 Gentamicin 1.0 g  DePuy  
CMW 2 Gentamicin 1.0 g DePuy 
SmartSet GHV Gentamicin 1.0 g DePuy 
SmartSet GMV Gentamicin 1.0 g DePuy 
Simplex P  Tobramycin 1.0 g Stryker 
Copal G+V Gentamicin + Vancomycin 0.5 g + 2.0 g  Heraeus 
Copal G+V Gentamicin + Clindamycin 1.0 g + 1.0 g Heraeus 
 
Table 5. Summary of mechanical properties for different PMMA nanocomposites. 
 Compressive 
strength 
(MPa) 
Bending 
strength 
(MPa) 
Bending 
Modulus 
(MPa) 
Fracture 
Toughness 
(MPam1/2) 
Vickers 
Hardness 
(MPa) 
Liposomes 
(L31)  
80.8 79 3200 3.0 26.6 
Mesoporous 
silica 
85 - 2100 - - 
Carbon nano-
tubes 
8.7 - - - - 
Hydroxyapatite 
nano-rods 
43.5 - - - - 
Clay nano-
tubes 
- 35 - - - 
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Table 6. Summary list of nanotechnology based antibiotic loaded PMMA bone cements. 
 
Nano-carrier % of 
NPs in 
bone 
ce-
ment 
Loading 
capacity of 
gentamicin 
Dura-
tion of 
release  
% of 
gentami-
cin 
released  
Test-
ed 
bacte-
ria  
Limitation Referen-
ce 
Liposomes   ---- 30 days 22 S. 
aureus 
-- [142] 
Mesoporous 
silica 
10 ---- 80 days 60 --- -- [143] 
Carbon nano-
tubes 
5 ---- 60 days 75 ---- Cytotoxici-
ty, 
negative 
impact on 
mechani-
cal 
properties 
[143] 
Hydroxyapatit
e nano-rods 
32 ---- 60 days 75 ---- Negative 
impact on 
mechani-
cal 
properties 
[143] 
Clay nano-
tubes 
5-7 10-15 10 days 60 S. 
aureus
, E. 
coli 
Burst 
release  
[144] 
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Table 7. Summary list of nanotechnology non-antibiotic based antimicrobial PMMA bone 
cements. 
Type of 
Antimic-
robial 
nanopar-
ticles 
% 
of 
NP
s 
in 
bo-
ne 
ce-
me
nt 
Dura
-tion 
of 
rele
a-se  
% of 
antimic-
robial 
released  
Antimic-
robial 
spectrum 
Tes-
ted 
bacte-
ria 
Mode of 
action 
Limitations Referen-
ce 
Chitosan 15 --- --- Broad 
spectrum 
(Gram 
positive  
and Gram 
negatibe) 
S. 
aureus, 
S. 
epider
midis 
Interacti
on with 
negativel
y 
charged 
cell wall 
and cell 
lysis. 
 [150] 
QCS  15 --- --- Broad 
spectrum 
(Gram 
positive  
and Gram 
negatibe) 
S. 
aureus, 
S. 
epider
midis 
Interacti
on with 
negativel
y 
charged 
cell wall 
and cell 
lysis. 
 [150] 
dendrime
r 
10 30 
days 
--- Broad 
spectrum 
(Gram 
positive  
and Gram 
S. 
aureus, 
 E coli,   
P. 
aerugi
Interacti
on with 
negativel
y 
charged 
Cytocompa
tibility  
problems 
[149] 
53 
 
negatibe) nosa cell wall 
and cell 
lysis. 
Silver 
nanoparti
cles  
1 28 
days  
 Broad 
spectrum 
(Gram 
positive  
and Gram 
negatibe) 
P. 
aerugi
nosa,  
A. 
baum
annii,  
 S. 
aureu
s,   
P. 
mirabi
lis 
Ag NPs 
or Ag 
ions can 
interact 
with 
DNA 
replicatio
n, 
respirato
ry chain 
and cell 
division. 
Negative 
effect on 
mechanical 
properties  
[155] 
oleic acid  
capped 
Silver 
nanoparti
cles  
0.0
5 
  Broad 
spectrum 
(Gram 
positive  
and Gram 
negatibe) 
S.aur 
beus 
MRS
A 
S. 
epider
midis 
A. 
baum
annii 
 
Ag NPs 
or Ag 
ions can 
interact 
with 
DNA 
replicatio
n, 
respirato
ry chain 
and cell 
division. 
 [156] 
Tiopronin 
capped 
Silver 
nanoparti
cles 
0.1   Broad 
spectrum 
(Gram 
positive  
and Gram 
negatibe) 
MRS
A 
Ag NPs 
or Ag 
ions can 
interact 
with 
DNA 
replicatio
 [157] 
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Table 8. Nano-formulations with potential use in bone cements. 
 
Nano-carrier 
system 
Antimicrobia
l loaded  
Duratio
n of 
release  
Loading 
efficienc
y  
Method of 
preparation  
Application Referenc
e 
LbL coated 
Mesoporous 
silica  
Gentamicin  10 
Days  
211 
µg/mg 
 Promising for 
future 
applications 
to coat 
biomedical 
device 
surfaces 
such as 
pacemakers 
[162] 
n, 
respirato
ry chain 
and cell 
division. 
Propyl 
paraben 
7 5  Broad 
spectrum 
antibacter
ial (Gram 
positive  
and Gram 
negatib) 
and 
antifungal 
activity 
S.aur
eus 
MRS
A 
S. 
epier
midis 
A. 
baum
annii 
Inhibition 
of the 
synthesis 
DNA and 
RNA or 
ATPases 
and 
phosphotr
ansferase
s 
 [181] 
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and other 
implanted 
devices. 
 Au Gentamicin 7 days 38µg/ml   [165] 
Ca-silicate Chlorhexidin
e  
9 days ---  intra-canal 
medication in 
dentistry or a 
new bone 
defect 
filling 
material for 
infected 
bone 
defects. 
[166] 
PLGA Gentamicin 16 
days  
22 µg/ml Emulsion 
evaporation  
Treating 
sepsis and 
Pseudomona
s infections 
[167] 
Hydroxyapatiti
e nano-rods 
Gallium 
nanoparticle
s   
--- 16% ultrasonic 
emulsificatio
n 
tissue 
engineering, 
wound 
healing, 
bone fracture 
repair, 
prevention of 
infections 
during 
implantation 
[168] 
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 Figure captions 
Figure 1 Total joint replacements undertaken during 2014: (a) Hip and (b) Knee prosthesis, 
adapted from National Joint Registry (NJR 2015). 
 
Figure 2   Total hip replacement: (a) cemented implant, (b) cementless implant. 
 
Figure 3   Cemented total hip replacement (functions of bone cement). 
 
Figure 4   The number of TKR procedures performed in the UK between the years 2003-
2014, adapted from NJR, 2015. 
 
Figure 5   The number of THR in UK between the years 2003-2014, adapted from NJR, 
2015. 
 
Figure 6    Free radical polymerization reaction of PMMA .  
 
Figure 7   Proposed liposome-Pluronics structure. 
 
Figure 8  Scheme of (a) GTMC mixed with bone cement (b) bone cement formulated with 
MSN at low loading and (c) effective diffusion network formed by MSN in PMMA based bone 
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